ASRS 43rd Annual Scientific Meeting | July 30-August 2, 2025 | Long Beach, California Last updated 6/27/2025

		ASRS 43rd Annual Scientific Meeting July 30-August 2, 2025 Long Beach, California	Last updated 6/27/2025	
		Wednesday, July 30		
6:45 AM	7:45 AM	Continental Breakfast		
7:45 AM	11:00 AM	Retina Surgical Summit (NO CME OR LIVESTREAM)		
		<u>Team Europe:</u> Carl Claes, MD; Carlos Mateo, MD; Marco Mura, MD; Zofia A. Nawrocka, MD, PhD; Tom H.	Moderators: Stanislao Rizzo, MD; Colin A. McCannel, MD	
		Williamson, MD, MBChB, FRCS, FRCOphth		
		<u>Team of the Americas</u> Martin Charles, MD; Alexandre Grandinetti, MD, PhD; Gabriela Lopezcarasa Hernandez,	Moderators: Maria H. Berrocal, MD; Sunil Srivastava, MD	
		MD; Virgilio Morales-Canton, MD; Carmen R. Negrin-Martin, MD; Cynthia X. Qian, MD		
		<u>Team Asia</u> Hussain Ahmad Khaqan, MD; Marie Joan Loy, MD, DPBO, FPAO; Manish Nagpal, MD, FRCS (UK),	Moderators: Yusuke Oshima, MD, PhD; Christina Y. Weng,	
		FASRS; Gavin Tan, MBBS, FRCSEd, FAMS, PhD; Taku Wakabayashi, MD, PhD; Wei-Chi Wu MD, PhD	MD, MBA, FASRS	
11:00 AM	11:30 AM	Lunch Break		
11:30 AM	12:30 PM	Retina Battle	Moderators: Kourous A. Rezaei, MD; David R. Chow, MD, FRCS(C)	
		Team 1 : Flavio A. Rezende, MD, PhD; Lejla Vajzovic, MD, FASRS; Yoshihiro Yonekawa, MD, FASRS		
		Team 2: Matteo Forlini, MD; Jorge A. Fortun, MD; Aleksandra V. Rachitskaya, MD, FASRS		
		Team 3: Audina M. Berrocal, MD, FASRS; John W. Kitchens, MD; Joel Pearlman, MD, PhD		
12:30 PM	1:30 PM	Retinaws (NO RECORDING)	Moderator: Kourous A. Rezaei, MD	
		Panelists: Maria H. Berrocal, MD; Geoffrey G. Emerson, MD, PhD, FASRS; Avni P. Finn, MD, MBA, FASRS; Sunir J.		
		Garg, MD, FACS, FASRS; J. Michael Jumper, MD, FASRS; Adrienne W. Scott, MD, FASRS; Gaurav K. Shah, MD;		
		Christina Y. Weng, MD, MBA, FASRS; Charlie C. Wykoff, MD, FASRS		
1:30 PM	3:00 PM	Surgical Case Conference		
		Presenters: Sulaiman M. Al Sulaiman, MD; Carmen Baumann, MD, PhD, FEBO; Barton Blackorby, MD;	Moderators: Dean Eliott, MD; Prithvi Mruthyunjaya, MD,	
		Subhendu Boral, MBBS, MD(AIIMS), DNB; Lawrence Chan, MD; Jonathan Chang, MD, FASRS; Geoffrey Emerson,	MHS; Lejla Vajzovic, MD, FASRS	
		MD, PhD, FASRS; Mallika Goyal, MD; Srinivas Joshi, MD, FASRS; Talia Kaden, MD; Aditya Kelkar, MS, FRCS,		
		FASRS,FRCOphth; Mark McAllister, MD; Sandra Montezuma, MD; Matthew Ohr, MD; Geovanni Rios, MD; Sami		
2.00.014	2 22 224	Uwaydat, MD; Christina Weng, MD, MBA, FASRS; Zhaotian Zhang, MD		
3:00 PM	3:30 PM			
3:30 PM	5:00 PIVI	Medical Case Conference	Andread County Annually AND Cristing D. Codds AND	
		Presenters: Nazanin Barzideh, MD, FASRS; Audina M. Berrocal, MD, FASRS; Andrew Farag, MD; Hong-Uyen Hua, MD; Harsh H. Jain, MBBS, DNB; George Jiao, MD; Colin A. McCannel, MD; Mohamed R. Mohamed, MD;	Moderators: Sruthi Arepalli, MD; Srinivas R. Sadda, MD; David Sarraf, MD	
			David Sarrai, IVID	
		Spencer M. Moore, MD, PhD; Kareem Moussa, MD; Robert A. Sisk, MD, FACS, FASRS; Bradley T. Smith, MD,		
		FASRS; Mudit Tyagi, MS, FASRS; Lejla Vajzovic, MD, FASRS; Rui Wang, MD; Yoshihiro Yonekawa, MD, FASRS; Yuxi Zheng, MD; James L. Zimmerman, MD		
6:00 PM	10.00 DN4			
6:00 PIVI	10:00 PIVI	Opening Reception: Ballast Point		
		Thursday, July 31		
6:30 AM		Experience Center (Fellows & Residents)		
6:45 AM		Fellowship Directors Breakfast		
7:30 AM		Continental Breakfast		
8:00 AM		Opening Comments	Gaurav K. Shah, MD	
8:05 AM		State of Retina	J. Michael Jumper, MD, FASRS	
8:10 AM		Retinal Detachment Symposium 1	Moderators: Lisa Olmos de Koo, MD, MBA; Yusuke	
3.20	0.10710		Oshima, MD, PhD; Tom H Williamson, MD, MBChB, FRCS,	
			FRCOphth	
		The Feasibility and Outcomes of Vitrectomy in the Office-Based Operation Room	Taku Wakabayashi, MD, PhD	8:10 AM
		The Use of Incorrect Intraocular Gas Tamponades During Vitreoretinal Surgery	Gaurav K. Shah, MD	8:13 AM
		Lincoff vs Artificial Intelligence: A Reappraisal of Lincoff's Rules for Finding the Retinal Tear	John T. Thompson, MD	8:16 AM
		Discussion		8:19 AM
		Minimally Invasive Suprachoroidal Buckling Using a Novel Injector: Preclinical Evaluation in Human Cadaver	Gareth D. Mercer, MD, PhD	
		Eyes		8:28 AM

			I	
		Preoperative OCT Biomarkers of Outer Retinal Alterations in Rhegmatogenous Retinal Detachment: Predictors	Eoi Jong EJ Seo, MD, PhD	
		of Postoperative Visual Outcomes		8:31 AM
		Evaluation of Macular Perfusion Post Rhegmatogenous Retinal Detachment Surgery Using Optical Coherence	Muhammad Amer R. Awan, MD, FRCSEd, FRCOphth, FRCS	
		Tomography Angiography: A Systematic Review and Meta-Analysis	Glasgow, FACS, FASRS	8:34 AM
		Discussion		8:37 AM
8:45 AM	9:20 AM	Retinal Detachment Symposium 2	Moderators: Carl C Awh, MD, FASRS; Mrinali Gupta,	
			MD,FASRS; Jeffrey S Heier, MD	
		Risk of Retinal Detachment in Fellow Eye With Lattice Degeneration After Primary Rhegmatogenous Retinal	Chase A. Ludwig, MD, MS	
		Detachment		8:45 AM
		Risk of New Retinal Tear or Detachment After Cataract Surgery in Patients With Previously Treated Phakic	Basil K. Williams, MD	
		Retinal Tears		8:48 AN
		Predictors of Primary Rhegmatogenous Retinal Detachment Surgical Revision	Ahmed F. Shakarchi, MD, MPH	8:51 AM
		Discussion		8:54 AM
		Lyophilized Amniotic Membrane Patches Are a Safe and Effective Treatment for Rhegmatogenous Lesions in	Angel Garcia, MD	
		Combined Tractional and Rhegmatogenous Retinal Detachment		9:02 AN
		Predictors of Primary Anatomic Reattachment With Pneumatic Retinopexy for Rhegmatogenous Retinal	Aurora Pecaku, MD	
		Detachment		9:05 AM
		Comparison of Retinal Detachment Repair Outcomes Using 20% Sulfahexafluoride (SF6) vs Air Tamponade in	Trent Chiang, MD, MS	
		Pars Plana Vitrectomy Surgery With or Without Scleral Buckle		9:08 AM
		Discussion		9:11 AM
9:20 AM	9:41 AM	Case-Based Panel Discussion: Surgery	Moderator: J. Michael Jumper, MD, FASRS	9:20 AV
9:41 AM		Invited Talk: What Every Retina Doctor Needs to Know About Neuro-ophthalmology	Andrew G. Lee, MD	9:41 AM
10:01 AM	10:41 AM		,	10:01 AM
10:41 AM	10:51 AM	Invited Talk: Diabetic Retinopathy: Underappreciated or Overemphasized Managements in 2025	Neil M. Bressler, MD	10:41 AM
10:51 AM		Diabetic Retinopathy Symposium 1	Moderators: Avni P Finn, MD, MBA, FASRS; Joel Pearlman,	
10.51 /		. , , ,	MD, PhD; Michael W Stewart, MD	
		Volumetric Analysis of Hard Exudates on Optical Coherence Tomography: Biomarker Results of Faricimab vs	Murtaza K. Adam, MD	
		Aflibercept From Phase 3 YOSEMITE/RHINE		10:51 AM
		Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From	Andres Emanuelli, MD	
		ELEVATUM in the United States	,	10:54 AN
		Update on Faricimab for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study	Veeral S. Sheth, MD, MBA, FASRS, FACS	
		Space of Fariance 15 2 men of mount entered of 2700 men one 11 one 12 neong from 2 neong to the control of the		10:57 AM
		Discussion		11:00 AM
		Comparability of Diabetic Retinopathy Severity Evaluation on Gold Standard vs Ultra-Widefield Images in	Barbara A. Blodi, MD	22.007
		YOSEMITE/RHINE Phase 3 Studies	Surgara Al Siouly Wis	11:09 AM
		VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for	Vasha S Modi MD	11.03 AIV
		Diabetic Macular Edema	Tushu S. Moul, MD	11:12 AN
Late-		PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in	Justis Ehlers, MD, FASRS	11.12 / 110
Breaking		Patients with Diabetic Retinopathy	Justis Elliers, Mid, FASKS	
Abstract		rations with biabetic retinopathy		11:15 AM
Abstract		Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema Switching	Michael Javaheri, MD	11.13 AIV
			Iviiciaei Javaileii, Ivib	11:18 AN
		From Other Anti-VEGF Agents Aflibercent 9 mg in Disbetic Macular Edoma: 1EG Wook Becults From the DHOTON Extension Study	Eric Schneider, MD	11:21 AV
		Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study Discussion	ETIC SCHILERGET, IVID	11:21 AIV
		INISCUSSION		11:24 AIV
44.25.484	42:45 DN4	Disk skip Bakin an akke Communition 2	BA - de materiario Colotto BA II - maletario BAD. Del BA - torri BAD.	
11:35 AM	12:15 PM	Diabetic Retinopathy Symposium 2	Moderators: Odette M Houghton, MD; Raj Maturi, MD; Dante J Pieramici, MD	
11:35 AM	12:15 PM	Diabetic Retinopathy Symposium 2 Interim Results From the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Diabetic		
11:35 AM	12:15 PM		Dante J Pieramici, MD	11:35 AM
11:35 AM	12:15 PM	Interim Results From the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Diabetic	Dante J Pieramici, MD	11:35 AM

			T	
		A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept or Faricimab, in Diabetic Macular Edema	Jeremiah Brown, MD, MS, FASRS	11:41 AV
		Longitudinal Quantitative Ultra-Widefield Retinal Leakage Assessment in Diabetic Retinopathy Following a Single Axitinib Hydrogel (OTX-TKI) in the HELIOS Trial	Katherine E. Talcott, MD	11:44 AV
		Suprachoroidal Avoralstat, a Plasma Kallikrein Inhibitor, Stops Vascular Leakage in a Well-Established Rabbit Model	Dilsher S. Dhoot, MD	11:47 AM
		Efficacy and Safety Outcomes over 12 weeks with OCS-01 Eye Drops in DME From DIAMOND-Stage 1 trial: Focus on Subgroup by Prior Treatment Status	Baruch D. Kuppermann, MD, PhD, FASRS	11:50 AM
		Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials	Dante Pieramici, MD	11:53 AM
		Discussion		11:56 AM
12:15 PM	12:36 PM	Case-Based Panel Discussion: Diabetic Retinopathy	Moderator: Charles C. Wykoff, MD, PhD, FASRS	12:15 PM
		Panelists: Andrew J. Barkmeier, MD; Jeremiah Brown Jr., MD, MS, FASRS; Matthew A. Cunningham, MD, FASRS; Christiana Dinah, BSc. MB BS, MRes; Christopher G. Fuller, MD; Roger A. Goldberg, MD, MBA		
12:36 PM	1:51 PM	General Lunch + WinR Lunch		12:36 PM
1:51 PM		Business Meeting - MEMBERS ONLY		1:51 PM
2:06 PM		Invited Talk: Future Treatments for Dry Macular Degeneration	David S. Boyer, MD	2:06 PM
2:16 PM		Dry AMD Symposium 1	Moderators: Susan B Bressler, MD, FASRS; Eleonora M Lad, MD, PhD; Andre J Witkin, MD	
		Baseline Characteristics Associated With Geographic Atrophy Progression in the OAKS and DERBY Trials	Srinivas R. Sadda, MD	2:16 PM
		Early vs Delayed Pegcetacoplan Treatment for GA Secondary to AMD: 48-Month Results From OAKS, DERBY, and GALE Open-Label Extension	Roger A. Goldberg, MD, MBA	2:19 PM
		Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program	Diana V. Do, MD, FASRS	2:22 PM
		Discussion		2:25 PM
		Complement Inhibition Treatment for Geographic Atrophy in Eyes With Exudative AMD	Josh O. Wallsh, MD	2:35 PM
		A Descriptive Analysis of Patients Who Received Pegcetacoplan and Anti-VEGF for the Treatment of Geographic Atrophy and Neovascular AMD	Nimesh A. Patel, MD, FASRS	2:38 PM
		Safety Profiles of Combined Anticomplement and Anti-VEGF Intravitreal Therapies for Age-Related Macular Degeneration From Real-World Data	Edward H. Wood, MD, FASRS	2:41 PM
		Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections	Ash Pirouz, MD	2:44 PM
		Discussion		2:47 PM
2:56 PM	3:36 PM	Dry AMD Symposium 2	Moderators: Glenn J Jaffe, MD; Jaclyn L Kovach, MD, FASRS; Camille V Palma, MD	
		The 12-Month Safety Results of the PRIMAvera Clinical Trial	Lisa C. Olmos de Koo, MD, MBA	2:56 PM
		ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design and Rationale Informed by Outcomes From ARCHER	David A. Eichenbaum, MD, FASRS	2:59 PM
		LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration	David S. Boyer, MD	3:02 PM
		Discussion		3:05 PM
		Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights From the Phase 3 OAKS and DERBY Trials	Paul Hahn, MD, PhD, FASRS	3:14 PM
		New AREDS Data Analyses on Whether AREDS Patients Should Have Routine Genetic Testing	Stephen R. Kaufman, MD	3:14 PM
		Genotype Prediction From Retinal Fundus Images Using Deep Learning in Eyes With Age-Related Macular Degeneration	Glenn C. Yiu, MD, PhD	3:17 PM
		Novel Handheld Device for Remote Monitoring of Non-neovascular Age-Related Macular Degeneration and Clinical Validation of Usability and Comfort	Yannis M. Paulus, MD	3:23 PM
		Discussion		3:23 PN 3:26 PN
3:36 PM	4:16 PM			3:36 PN

4:16 PM	4:46 PM	Macular Pucker - Epiretinal Membrane & Macular Holes Symposium 1	Moderators: J. Fernando Arevalo, MD, PhD, FACS, FASRS; Margaret Chang, MD, MS; Yoshihiro Yonekawa, MD, FASRS	
		First Applications of Digital Surgery in Ophthalmology	Stanislao Rizzo, MD	4:16 PM
		Double Agents of the Vitreous: An En Face OCT Study of Hyalocytes Post Vitrectomy	Richard B. Rosen, MD, DSc(Hon), FACS, FASRS, FARVO	4:19 PM
		The Role of Preoperative En Face OCT to Identify Non-internal Limiting Membrane Peeling Candidates for	Kotaro Tsuboi, MD	
		Macular Hole Surgery		4:22 PM
		Large Preretinal Human Amniotic Membrane Graft for Chronic or Persistent Macular Holes	Aristomenis Thanos, MD	4:25 PM
		Long-Term 10-Year Results After the Inverted ILM Flap Technique for Full-Thickness Macular Holes	Zofia Anna A. Nawrocka (vel Michalewska), MD, PhD	4:28 PM
		Discussion		4:31 PM
4:46 PM	5:16 PM	Macular Pucker - Epiretinal Membrane & Macular Holes Symposium 2	Moderators: Eric W Schneider, MD; John T Thompson,	
			MD; Lejla Vajzovic, MD, FASRS	
		OCT-Angiography (OCTA)-Guided Single-Day Intense Prone Positioning in Macular Hole Surgery	Subhendu Boral, MBBS, MD(AIIMS), DNB	4:46 PM
		Closure Patterns in Macular Holes With Epiretinal Membranes and Correlation With Surgical Technique	Raja Rami P. Reddy, MD, FRCS, FASRS	4:49 PM
		5-Year Functional and Anatomical Outcomes in Eyes With Idiopathic Epiretinal Membranes Following Surgical Removal	Lihteh Wu, MD	4:52 PM
		Hyperacute Epiretinal Membranes After Retinal Detachment Repair: Anatomic Characteristics, Onset, Progression, and Surgical Timing	Vivek Chaturvedi, MD, FASRS	4:55 PM
		Management of Retinal Detachment With Coexisting Macular Hole (MHRD) in the Adult Age Group: Functional and Anatomical Outcome	Pramod S. Bhende, MS	4:58 PM
		Discussion		5:01 PM
5:16 PM	5:37 PM	Panel Discussion on Paper-on-Demand Presentations: Themes by Topics	Moderators: Matthew Starr, MD, FASRS; Manjot K Gill, MD, MS, FRCS (C), FASRS	5:16 PM
		Panelists: Sruthi Arepalli, MD; Frank Brodie, MD, MBA; Georgia Kambjoj, MBBS, PhD; Bradley T Smith, MD, FASRS; Priya S Vakharia, MD, FASRS		
5:37 PM	6:37 PM	Scientific Poster Q&A and Exhibit Hall Reception		5:37 PM
6:37 PM	7:33 PM	FIT/Resident Retina Jeopardy		
		Friday, August 1		
		ASRS FOUNDATION RETINA IN ACTION 5k Run/Walk. Sponsored by PRISM Vision Group		
6:30 AM		Experience Center (Fellows & Residents)		
7:00 AM		International Affairs Case Conference Breakfast		
7:30 AM		Continental Breakfast	And I am I a	
8:00 AM	8:40 AM	Surgical Techniques Symposium 1	Moderators: Audina M Berrocal, MD FASRS; Philip J Ferrone, MD, FASRS; Rajeev H Muni, MD, MSC, FRCS(C), FASRS	
		Comparison of Traction Force between Current-Generation and Next-Generation Vitrectomy Systems (25-Gauge)	Steve T. Charles, MD, FASRS, FACS, FICS	8:00 AM
		Functional Assessment of a Novel 27-Gauge Multi-Spot Laser Probe in a Surgical Simulation Bioniko Eye Model	Kourous A. Rezaei, MD	8:03 AM
		The Safety, Brightness and Clinical Options of the LED RGB Light Source on the UNITY Vitreoretinal Cataract System (VCS) Platform	David R. Chow, MD, FRCS(C)	8:06 AM
		Discussion		8:09 AM
		Volumetric Evaluation of Novel Single-Step Subretinal Injection Device Using Microscope-Integrated Optical Coherence Tomography	Lejla Vajzovic, MD, FASRS	8:17 AM
		Secondary Scleral-Sutured Toric Intraocular Lens for Astigmatic Correction in the Absence of Capsular Support	Matthew Starr, MD	8:20 AM
		Eight year Outcomes of Pars Plana Vitrectomy and Scleral-Fixated Intraocular Lens Using Gore-Tex Sutures	Luis A. Acaba-Berrocal, MD	8:23 AM
		First-in-Human Outcomes of a Sutureless, Scleral-fixated, Prosthetic Capsular Bag	J. Michael Jumper, MD, FASRS	8:26 AM

		Discussion		8:29 AM
8:40 AM	9:20 AM	Surgical Techniques Symposium 2	Moderators: Tarek S Hassan, MD, FASRS; Carl D Regillo, MD, FACS; Katherine E Talcott, MD	
		Postoperative Day 0 as a Substitute for Postoperative Day 1 Examination Following Vitreoretinal Surgery: A	Christina Y. Weng, MD, MBA, FASRS	
		Comparative Prospective Study	This time in vierig, they trusted	8:40 AN
		Drop less Vitrectomy with 'Suprachoroidal Trimoxi': A Comparative Analysis of Safety and Efficacy with	K. V. Chalam, MD, PhD, MBA, FRCS(C), FASRS	0
		standard of care topical drops		8:43 AM
		A Prospective Assessment of the ASRS Surgical Log as a Tool to Accurately Assess Fellow Role and Performance	Alexander Melamud, MD, MA	
		in Surgery	,	8:46 AN
		Discussion		8:49 AN
		Combined Vitrectomy and Reduced-Dose Transscleral Diode Laser Cyclopexy for Managing Large Cyclodialysis	Mauricio Bayram-Suverza, MD	
		Clefts: A Vitreoretinal Approach	, , , , , , , , , , , , , , , , , , , ,	8:58 AM
		Modified Simple Silicone Materials in T-Shaped Macular Buckling Surgery	Yodpong Chantarasorn, MD	9:01 AN
		Visual Outcomes After 1-Stage vs 2-Stage Surgery for Intraocular Foreign Body Removal and Open-Globe	Jinghua Chen, MD, PhD	
		Repair, Multicenter Study		9:04 AM
		Low-Dose Atropine 0.01% Drops for Symptomatic Vitreous Floaters: A Noninvasive, Safe, and Effective	Mohsin H. Ali, MD	
		Therapeutic Option		9:07 AM
		Discussion		9:10 AM
9:20 AM	9:55 AM	Surgical Complications Symposium	Moderators: Jorge A Fortun, MD; Vivienne S Hau, MD, PhD; Sunil Srivastava, MD	
		Early Vitrectomy vs Intravitreal Antibiotics Only for Postinjection Endophthalmitis: An IRIS (Intelligent Research	Andrew C. Lin, MD	
		in Sight) Registry Report	Andrew Cremy MB	9:20 AM
		Cataract Surgery Complications in Individuals Who Previously Received Intravitreal Injections	Peter J. Kertes, MD, FRCS(C)	9:23 AM
		The Impact of Prefilled Syringe Technology on Rates of Endophthalmitis Following Intravitreal Injection of	Philip P. Storey, MD, MPH	
		Faricimab		9:26 AM
-		Diagnostic Yield of Diluted Aqueous Fluid Analyzed With Polymerase Chain Reaction Testing in the Workup of	Mariam Mathai, MD	3.207.11
		Infectious Uveitis		9:29 AM
-		Long-Term Visual and Surgical Outcomes in 33 Eyes With Noninfectious Uveitis Requiring Secondary Lens	Sruthi Arepalli, MD	
		Implantation	or a time of a t	9:32 AN
ellows		Retinal Complications After Cataract Surgery for Adult Patients With a History of Retinopathy of Prematurity:	Nikhil Bommakanti, MD	
orum		An IRIS (Intelligent Research in Sight) Registry Analysis	,	
Award		· (· · · · · · · · · · · · · · · · · ·		
Vinner				9:35 AM
		Discussion		9:38 AN
9:55 AM	10:35 AM	Break		
10:35 AM	11:15 AM	Wet AMD Symposium 1	Moderators: David M Brown, MD, FASRS; Justis Ehlers,	
			MD, FASRS; Mark Humayun, PhD, MD, FASRS	
		Baseline and Early Treatment Response Variables Associated With Faricimab Durability in Treatment-Naive	Benjamin Bakall, MD, PhD	
		nAMD: TENAYA/LUCERNE Post Hoc Analyses		10:35 AM
		Rapid Fluid Resolution With Aflibercept 8 mg May Be Associated With Extended Dosing Intervals at Week 96 in	Michael W. Stewart, MD	
		nAMD: A PULSAR Post Hoc Analysis		10:38 AM
		PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With	David T. Wong, MD, FRCS(C), DRCPSC, FASRS	
		Neovascular Age-Related Macular Degeneration		10:41 AM
		Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in DME and nAMD	Nikolas J. London, MD, FACS, FASRS	10:44 AN
		5-Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS	John W. Kitchens, MD	10:47 AM
			Veren M. Mei MD	
_ate-		Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal	Karen M. Wal, MD	
Late- Breaking		Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal	Karen IVI. Wai, IVID	
		Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal	karen IVI. Wal, IVID	10:50 AM
Breaking		Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Efficacy and Safety of Biosimilar Aflibercept-ayyh in Clinical Use by a Consortium of Retina Practices	Carl Awh, MD, FASRS	10:50 AM 10:53 AM

12:00 PM	Wet AMD Symposium 2	Moderators: Robert L Avery, MD; Sophie J Bakri, MD; Paul Hahn, MD, PhD, FASRS	
	Treatment Burden in Wet Age-related Macular Degeneration Treated with EYP-1901 Versus Aflibercept in the	Avni P. Finn, MD, MBA, FASRS	
l	DAVIO 2 Phase 2 Clinical Trial		11:15 AM
	Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of	Jennifer I. Lim, MD, FARVO, FASRS	
ļ	Neovascular Age-Related Macular Degeneration		11:18 AM
	COAST: A Phase 3 study of intravitreal sozinibercept combined with aflibercept in participants with neovascular	Charles C. Wykoff, MD, PhD, FASRS	
l	age-related macular degeneration		11:21 AM
	PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular	John A. Wells, MD, FACS	
ļ	Degeneration: 52-Week Results		11:24 AM
	Vials vs Prefilled Syringes (PFS): Intraocular Pressure (IOP) Spikes From 151,657 Intravitreal Injections (IVIs)	Ian YL Yeung, MA, FRCOphth	
ļ	From 2010 to 2025 From a Single Center in the United Kingdom		11:27 AM
	Real-World Intraocular Pressure (IOP) and Glaucoma Outcomes From Intravitreal Treatments Based on	Deepak Sambhara, MD	
ļ	Injection Volume	•	11:30 AM
		Sami H. Uwavdat. MD	11:33 AM
		, .	11:36 AM
			11:39 AM
12:31 PM		Moderators: J. Michael Jumper, MD. FASRS: Reginald J.	
	······································		
	Pyron Award Introduction	· ·	12:51 PM
			12:53 PM
			12:58 PM
			1:00 PM
			1:05 PM
ļ	, , , , , , , , , , , , , , , , , , ,		1:07 PM
		I. Michael lumper. MD. FASRS	1:12 PM
	, ,		1:14 PM
ļ	The time time ge built time ge of the real	==	1:16 PM
-	Retina Atlas Chanter of the Year		1:17 PM
			1:18 PM
	1 , ,		1:20 PM
1:46 DM		John 1. Monipson, Wib	1.2011
		Moderators: Sahin Dang MD: Pohert A Mittra MD	
2.101101	week Altib Symposium S	_	
	1-Vaar Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ARRV-		
l		Nobel C. Avery, IVID	1:46 PM
		Harit K Rhatt MD MRA FASRS FACS	1.40110
l		Traile R. Briatt, Wib, WibA, LASIG, LACS	1:49 PM
		Soan D. Adream MD. EAAO. EASPS	1.45110
ŀ		Jean D. Aulean, MD, I AAO, FAJRJ	1:52 PM
		S Krishna Mukkamala MD EASPS	1.52 F IV
ŀ		3. Kilsiilia Wakkailiala, WD, LASKS	1:55 PM
		Sonhie I Bakri MD	1.JJ F IV
ŀ		Soprile 3. Dakii, Mid	1:58 PM
			2:01 PN
2.27 DM	Case-Based Panel Discussion: Wet AMD	Moderator: Christina Y. Weng, MD, MBA, FASRS	2:16 PM
		HVIOUETALUI, CIIIISIIIA I. VVEIIS, IVID, IVIDA, FASKS	2.10 PIV
	Panelists: Robert L Avery, MD; Sophie J Bakri, MD; Joseph M Coney, MD, FASRS; Diana V Do, MD, FASRS;	8,,	
	12:31 PM	Treatment Burden in Wet Age-related Macular Degeneration Treated with EYP-1901 Versus Aflibercept in the DAVIO 2 Phase 2 clinical Trial Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration COAST: A Phase 3 study of intravitreal sozinibercept combined with aflibercept in participants with neovascular age-related macular degeneration PRISM Phase 2 bc Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results Vials vs Prefilled Syringes (PFS): Intraocular Pressure (IOP) Spikes From 151,657 Intravitreal Injections (IVIs) From 2010 to 2025 From a Single Center in the United Kingdom Real-World Intraocular Pressure (IOP) and Glaucoma Outcomes From Intravitreal Treatments Based on Injection Volume Acute Optic Nerve Anatomic Changes Following Intravitreal Injection of Pharmaceutical Agents Swing vs Flick: Assessing Safer Air Bubble Removal Techniques in Intravitreal Injections Discussion 12:31 PM Awards Ceremony Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Founders Award: Introduction Pyron Award Introduction Pyron Award: The Beauty of Inverted ILM Flap Young Investigators Award Introduction Young Investigators Award: From Gonin's Theory to Machemer's Vitrectomy and Back Again: Coming Full Circle in Rhegmatogenous Retinal Detachment Repair Packo Award Presentation to Kevin J. Blinder, MD, FASRS Crystle Apple Award Presentation to Kevin J. Blinder, MD, FASRS Crystle Apple Award Presentation to Sunil Srivastava, MD Retina Hall of Fame Award 1:46 PM Retina Hall of Fame Face Section Lunch 2:16 PM Retina Hall of Fame Face Section Lunch Retina Hall of Fame Face Section Lunch Retina Hall of Fame Face Section Lunch Retina Hall of Fame	Treatment Burden in Wet Age-related Macular Degeneration Treated with EYP-1901 Versus Affibercept in the DAVIO 2 Phase 2 Clinical Trial Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Affibercept for Treatment of Neovascular Age-Related Macular Degeneration COAST. A Phase 3 study of Introductar Degeneration COAST. A Phase 3 study of Introductar Degeneration PRISM Phase 25 Clinical Trial Evaluating introductar degeneration PRISM Phase 25 Clinical Trial Evaluating introductar Pressure (IOP) Spikes From 151, 657 Introductar Age-Related Macular Degeneration 152-Week Results Vials vs Prefilled Syringes (IPS): Intraocular Pressure (IOP) spikes From 151, 657 Introductar Age-Related Macular Degeneration 152-Week Results Vials vs Prefilled Syringes (IPS): Intraocular Pressure (IOP) and Glaucoma Outcomes From Intravitreal Injections (IVIs) from 2010 to 2035 From 3 single Center in the United Kingdom Real-World Intraocular Pressure (IOP) and Glaucoma Outcomes From Intravitreal Injections of Pharmaceutical Agents Swing vs Flick: Assessing Safer Air Bubble Removal Techniques in Intravitreal Injections Obcoussion Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retinal Science to Restore Vision Pyron Award: Illuminating the Unknown: Advancing Retina

2:37 PM	2:47 PM	Invited Talk: How to Manage Nevi Day to Day for the Vitreoretinal Surgeon	Amy C. Schefler, MD, FACS, FASRS	
2:47 PM	3:22 PM	Ocular Oncology Symposium	Moderators: Tara A McCannel, MD, PhD; Prithvi	
			Mruthyunjaya, MD, MHS; Basil K Williams, MD	
		Gene Expression Profiling Accurately Predicts Mortality for Medium and Large Uveal Melanoma: Improved	Timothy G. Murray, MD, MBA, FASRS	
		Survival Outcomes for Class 1a Greater Than Class 1b Greater Than Class 2		2:47 PM
		Detection of Germline BAP1 Mutations in Patients With Uveal Melanoma	Amy C. Schefler, MD, FACS, FASRS	2:50 PM
		Independent Validation of a 16-Protein Test to Assess Malignant Potential of Small Uveal Melanocytic Tumors	David A. Reichstein, MD	
				2:53 PM
		Discussion		2:56 PM
		Racial and Ethnic Disparities in Retinoblastoma Treatment Options: A Multi-institutional TriNetX Analysis	Vivienne S. Hau, MD, PhD	
				3:04 PM
		$\label{thm:condition} Endodiode\ Laser\ With\ Vitrectomy-Transretinal\ Biopsy\ (EDL-VitBx)\ for\ Treatment\ of\ T1\ and\ T2\ Uveal\ Melanoma:$	Scott C. Oliver, MD	
		Initial Results of Vision-Sparing, Definitive Local Therapy		3:07 PM
		Retinal Pigment Epithelium Undulations in Primary Vitreoretinal Lymphoma: Hidden Paradox	Vishal R. Raval, MBBS, DNB, FMRF, FASRS	3:10 PM
		Discussion		3:13 PM
3:22 PM	3:43 PM	Case-Based Panel Discussion: Ocular Oncology	Moderator: Timothy G. Murray, MD, FASRS	
		Panelists: Ivana K. Kim, MD; Scott C. Oliver, MD; David A. Reichstein, MD; Basil K. Williams, MD		
3:43 PM	4:23 PM	Break		
4:23 PM	4:33 PM	Invited Talk: Genetic Testing for the Retina Specialist: What You Need to Know	Aaron Nagiel, MD, PhD	
4:33 PM	5:08 PM	Hereditary Retinal Disease & Genetics Symposium 1	Moderators: Robert E MacLaren, DSc DPhil FRCS	
			FRCOphth FACS FMedSci; Yasha S. Modi, MD	
		Retinal Gene Therapy Surgical Techniques	Robert E. MacLaren, DSc, Dphil, FRCS, FRCOphth, FACS,	
			FMedSci	4:33 PM
		Subretinal Laru-zova Gene Therapy for XLRP: 24-Month Results of the Randomized, Controlled, Multicenter	Robert A. Sisk, MD, FACS, FASRS	
		Phase 2 SKYLINE Trial		4:36 PM
		A Novel Modifier Gene Therapy for Retinitis Pigmentosa: 2-Year Results of a Phase 1/2, Multicenter, Dose-	Syed Shah, MD	
		Escalation Study of Subretinal OCU400		4:39 PM
		Discussion		4:42 PM
		Extended Efficacy and Safety of MCO-010 Optogenetic Therapy for RP: 126-Week Results From the RESTORE	David S. Liao, MD, PhD	
		Follow-Up Study (REMAIN)		4:50 PM
		Oral Gildeuretinol Slows Disease Progression in Early Stargardt Disease: Updates From the TEASE-3 Study	Kenneth C. Fan, MD, MBA	
				4:53 PM
		Secretion of Ciliary Neurotrophic Factor by NT-501 Encapsulated Cell Technology in Patients With Retinal	Jiong Yan, MD	
		Degenerative Disorders		4:56 PM
		Discussion		4:59 PM
5:08 PM	5:28 PM	Hereditary Retinal Disease & Genetics Symposium 2	Moderators: Nieraj Jain, MD, FASRS; Pradeep S Prasad, MD, MBA	
		Key Determinants Influencing Molecular Confirmation After Genetic Testing for Inherited Retinal Dystrophies	Joao Pedro Marques, MD, MSc, PhD, FEBOphth	
				5:08 PM
		Peripheral Retinal Vessels in Retinitis Pigmentosa	Hossein Ameri, MD, PhD, FRCSI, MRCOphth	5:11 PM
		North Carolina Macular Dystrophy: Haplotype Analysis of 31 Families Shows Single Founders for Each Mutation	Kent W. Small, MD, FASRS, FACS	
				5:14 PM
		Comparison of Retinal Layer Thicknesses After Macular Hole Surgery and Alport Syndrome	Gursel Yilmaz, MD, FEBO, FACS, FASRS	5:17 PM
		Discussion		5:20 PM
5:28 PM	5:46 PM	Pediatric Retina - ROP Symposium	Moderators: Prethy Rao, MD, MPH; Wei-Chu Wu, MD, PhD	
		P-Score Variability in Retinopathy of Prematurity as a Function of Image View, Capture Time, and Disease	Darius M. Moshfeghi, MD, FASRS	
		Severity		5:28 PM
		Evaluating Clinical Signs of Regression in Eyes Treated With Intravitreal Bevacizumab for Type 1 Retinopathy of	Yuxi Zheng, MD	
		Prematurity		5:31 PM

		Familial Fundative Vitua exating mathy (FFVD). Construe Phanature Associations and Misroussesular	Auding M. Downson MD. FACDS	1
		Familial Exudative Vitreoretinopathy (FEVR): Genotype-Phenotype Associations and Microvascular	Audina M. Berrocal, MD, FASRS	F.24 DN4
		Abnormalities on Optical Coherence Tomography (OCTA)		5:34 PM
F. AC DDA	7:24 004	Discussion Man Conference		5:37 PM
5:46 PM	7:31 PM	WinR Case Conference		
		C-1d A		
C:00 AB4	0.00 414	Saturday, August 2		
6:00 AM		URIM Mentoring Session		
6:30 AM		Experience Center (Fellows & Residents)		
7:30 AM		Continental Breakfast	24 1 25 124 124 124 125 124 125	
8:00 AM	9:05 AM	Practice Management & Socioeconomics Symposium	Moderators: Michael M Lai, MD, PhD; Linda A Lam, MD, MBA, FASRS; Reginald J Sanders, MD, FASRS	
		Accuracy of Initial Anti-VEGF Treatment Selection in Newly Diagnosed Neovascular Age-Related Macular	Prithvi R. Bomdica, MD, MBA	8:00 AN
		Degeneration: Retina Specialist Choice vs Step Therapy		
		Economic Impact of Anti-Vascular Endothelial Growth Factor Prior Authorization Process	Ella H. Leung, MD	8:03 AM
		Retinal Procedure Volume and Inflation-Adjusted Medicare Reimbursement in the 21st Century	Ron A. Adelman, MD, MPH, MBA	8:06 AM
		Discussion		8:09 AM
		Analysis of Antivascular Endothelial Growth Factor Utilization Trends and Prescriber Characteristics Based on	Stephanie B. Engelhard, MD	8:17 AM
		Medicare Part B Claims Data: 2017-2022		
		Comparative Cost Analysis of Secondary Intraocular Lens Surgeries Using Time-Driven, Activity-Based Costing	Warren W. Pan, MD, PhD	8:20 AM
		Take Out the Trash: Environmental Burden Associated With Intravitreal Injections	Abdullah Abou-Samra, MD	8:23 AM
		Discussion	,	8:26 AM
Late-		Comparative Facility Time-Based Financial Efficiency Coefficient Analysis of Retinal Surgery versus Cataract	Miguel Busquets, MD, FACS, FASRS	8:35 AM
Breaking		Surgery in Ambulatory Surgery Centers		
Abstract		G- / / G- /		
Late-		The Impact of Good Days' Underfunding on Retinal Disease Management: Insights from a National Survey of	Michael Lai, MD, PhD	8:38 AM
Breaking		American Society of Retina Specialists Members		
Abstract				
Late-		Changes in Retinal Disease Treatment Patterns Due to Copay Assistance Loss: A Real-World, Multi-Indication	Ghassan Ghorayeb, MD	8:41 AM
Breaking		Analysis Using Vestrum Retinal Health Database	, , ,	
Abstract		.,		
		Discussion		8:44 AM
		Good Days Panel Discussion		8:55 AM
9:05 AM	9:15 AM	Invited Talk: Amniotic Membrane in Vitreoretinal Surgery: When and How	Stanislao Rizzo, MD	9:05 AM
9:15 AM		Retinal Detachment Symposium 3	Moderators: Dean Eliott, MD; Aleksandra V Rachitskaya, MD, FASRS; Gaurav K Shah, MD	
		Primary Retinal Detachment Repair in Eyes Deemed High Risk for Proliferative Vitreoretinopathy: Surgical	M. Ali Khan, MD, FACS, FASRS	9:15 AM
		Outcomes in 605 Eyes	The talking triby tribby tribby	3.13 /101
 		Interim Report of the FIXER Trial: Prevention of ProliFerative Vitreoretinopathy With Intravitreal MethotreXate	Christopher D. Riemann, MD	9:18 AM
		in Primary Retinal DEtachment Repair	Caracopher D. McHain, 1910	J.10 AIV
 		Intravitreal Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy in Pediatric	Philip J. Ferrone, MD, FASRS	9:21 AM
		Patients	Timp 3. Terrolle, MD, LASKS	3.21 AIV
		Discussion		9:24 AM
		Hypotony Rates After Vitrectomy for PVR: Insights on Intravitreal MTX Use	Mostafa Mafi, MD	9:33 AM
		Encirclage and External Drainage to Enhance Vitrectomy Outcomes in Chronic Rhegmatogenous Retinal	Jayant Dr Kumar, MBBS, MS, DNB, MNAMS, FICO, FVRS	9:36 AM
		Detachment with Extensive PVR: A Retrospective Study	Jayant Di Kulliai, IVIDDS, IVIS, DIVD, IVIIVAIVIS, FICO, FVRS	9.30 AIV
-			Loo A Kim MD BhD	9:39 AM
 		From Bench to Bedside: Investigating the Use of Netarsudil as a Novel Therapeutic Approach for PVR	Leo A. Kim, MD, PhD	9:39 AM
		Postoperative Methotrexate Injections Decrease Reoperation Rate and Improve Vision Following Vitrectomy for PDR and Complex Retinal Detachments	MIGHT J. FTGHIKHH, IVID, PHD, PASKS	9.42 AIVI
-		Discussion		9:45 AM
		וטוכענטטועוו		9.45 AIVI

9:55 AM	10:35 AM	Break		9:55 AM
10:35 AM	11:15 AM	Retinal Detachment Symposium 4	Moderators: Maria H Berrocal, MD; J. Michael Jumper, MD, FASRS; Carlos Mateo, MD	
		Anatomical and Functional Outcomes of Vitrectomy for the Management of Longstanding Closed Funnel Retinal Detachments: A Single-Center Study	Malek Yassine, MD	10:35 AM
		Assessment of Redetachment Based on Proliferative Vitreoretinopathy Findings on SS-OCT	Isabela Martins Melo, MD	10:38 AM
		Association of Serum Vitamin D Insufficiency With Proliferative Vitreoretinopathy After Rhegmatogenous Retinal Detachment Repair	Steven D. Ness, MD	10:41 AM
		Novel Technique of Perfluoro-n-Octane (PFO): Guided Retinectomy Improves Single-Surgery Anatomic Success (SSAS) in Eyes With Proliferative Vitreoretinopathy (PVR)	Ajay E. Kuriyan, MD, MS	10:44 AM
		Comparative Cost Analysis of Pediatric and Adult Retinal Detachment Repairs Using Time-Driven, Activity-Based Costing	Nita Valikodath, MD, MS	10:47 AM
		Learning Curve of Scleral Buckling Surgery: The Journey of a Retina Fellow's First 100 Surgeries	Pallavi Priya, MS	10:50 AM
		The Reservoir Technique for Silicone Oil Placement: Intraocular Pressure Control and Long-Term Outcomes	Kathleen R. Schildroth, MD	10:53 AM
		Discussion		10:56 AM
11:15 AM		Invited Talk: OCT Biomarkers for Surgical Retinal Disorders	Srinivas R. Sadda, MD	11:15 AM
11:25 AM	11:40 AM	Best of JVRD Panel	Moderator: Timothy G. Murray, MD, MBA, FASRS	11:25 AM
		Panelists: David RP Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS; Carl D Regillo, MD; Steven D Schwartz, MD		
11:40 AM	12:15 PM	Dry AMD Symposium 3	Moderators: David S Boyer, MD; Jennifer I Lim, MD, FARVO, FASRS; David Sarraf, MD	
		Safety and Efficacy of OCU410, a Novel Modifier Gene Therapy, for Treatment of Geographic Atrophy: Phase 1/2 Study Update	Jay Chhablani,	11:40 AM
		Changes in Hyperautofluorescence Area and RPE/Outer Retinal Layer Thickness in the Phase 2a SIGLEC Study Assessing AVD-104 for the Treatment of GA	Carl D. Regillo, MD	11:43 AM
		Safety, Tolerability, and Properties of Novel C3 Inhibitor BI-C in Patients With Geographic Atrophy	Isabela Martins Melo, MD	11:46 AM
		Deactivation of CD163+ Retinal Macrophages With AVD-104 Siglec Agonism Can Restore Photoreceptor Function and Vision in Geographic Atrophy	Eleonora M. Lad, MD, PhD	11:49 AM
		Biomarker-Based Efficacy Analysis of Intravitreal CFH Supplementation in a Phase 2 Trial	David M. Brown, MD	11:52 AM
ate-		First Time Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy	TBD	11:55 AM
Breaking Abstract		rist fille results of vortion, a novel, compenient-woodlating delie merapy for deographic attorny		11.55 AIVI
		Discussion		11:58 AM
12:15 PM	12:45 PM	Dry AMD Symposium 4	Moderators: Alan J Franklin, MD, PhD, FASRS; Manish Nagpal, MD, FRCS (UK), FASRS; Richard B Rosen, MD, DSc(Hon), FACS, FASRS, FARVO	
		A 'Digital Twin' Approach to Modeling Geographic Atrophy Growth	Naresh Mandava, MD	12:15 PM
		Delayed Near-Infrared Analysis (DNIRA) Identifies Novel and Changing Features of Nonexudative (Dry) Age- Related Macular Degeneration (AMD): A Longitudinal Study	Shelley R. Boyd, MD, FRCS(C)	12:18 PM
		Vessel density changes in choroid, chorioâ€@apillaries, deep and superficial retinal plexues on OCTA in various stages of ARMD	Prashant K. Bawankule, MS	12:21 PM
		Retro-Mode (RM): A Newer Insight Into Dry Age-Related Macular Degeneration	Shilpi H. Narnaware, ICO (Retina) , FAICO (Vitreo-Retina)	12:24 PM
		Elamipretide Protection Against Photoreceptor Loss in Dry AMD: Predictive Baseline Quantitative Ellipsoid Zone Integrity Parameters in ReCLAIM-2	David R. Lally, MD	12:27 PM
		Discussion		12:30 PM
12:45 PM	12:52 PM	PAT Survey	Paul Hahn, MD, PhD, FASRS	12:45 PM
12:52 PM	12:55 PM	Global Trends	Sunir J Garg, MD, FACS, FASRS	
12:55 PM	2:10 PM	General Lunch + BOR Lunch		12:52 PM

2:10 PM	2:20 PM	Creative Awards		2:07 PM
2:20 PM	3:00 PM	Diabetic Retinopathy Symposium 3	Moderators: Kevin J Blinder, MD, FASRS; Rahul N	
			Khurana, MD, FASRS; Judy E Kim, MD, FARVO, FASRS	
		Outcomes of Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in	Rahul N. Khurana, MD, FASRS	2:20 PM
		the United States Who Were Lost to Follow-up		
		Incidence of Sight-Threatening Pathology Detected by Non-Mydriatic Fundus Photography in a National	Shawn C. Kavoussi, MD	2:23 PM
		Diabetic Screening Platform		
		Lower Socioeconomic Status Is Associated With Increased Bevacizumab Use Among Patients Initiating Anti-	Judy E. Kim, MD, FARVO, FASRS	2:26 PM
		VEGF Therapy for Diabetic Macular Edema		
		Neighborhood-Level Characteristics Associated With Delay in Surgery and Loss to Follow-up in Tractional	Sally S. Ong, MD	2:29 PM
		Retinal Detachment Due to Proliferative Diabetic Retinopathy		
		Diagnosis of Chronic Kidney Disease Using Retinal Imaging and Urine Dipstick Data: A Multimodal Deep	Joonhyung Kim, MD, PhD	2:32 PM
		Learning Approach		
		ChatGPT for Diabetic Retinopathy Screening	Saeed Mohammadi, MD	2:35 PM
		Systemic Biomarkers and Retinal Microvascular Alterations as Noninvasive Indicators of Diabetic Retinopathy	Kasra Rezaei, MD	2:38 PM
		and Nephropathy Severity and Diagnosis		
		Discussion		2:41 PM
3:00 PM	3:40 PM	Diabetic Retinopathy Symposium 4	Moderators: Geoffrey G Emerson, MD, PhD, FASRS; Rishi	
			P Singh, MD; Christina Y Weng, MD, MBA, FASRS	
		The Association of Pars Plana Vitrectomy With the Progression From Nonproliferative to Proliferative Diabetic	Ahmed B. Sallam, MD, PhD, FRCOphth	3:00 PM
		Retinopathy		
		The Risk of Hypoglycemia in Diabetes: An Outcomes-Based Analysis	Shree K. Kurup, MD	3:03 PM
		Risk Factors for Diabetic Retinopathy Progression During Pregnancy	Majda Hadziahmetovic, MD	3:06 PM
		Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use: Comparative Effectiveness of Semaglutide,	Andrew J. Barkmeier, MD	3:09 PM
		Dulaglutide, Liraglutide, and Exenatide		
		Reduced Rates of Diabetic Retinopathy Complications With Use of Continuous Glucose Monitoring: A	Ehsan Rahimy, MD	3:12 PM
		Multicenter Population-Based Study		
		Peripheral Visual Fields in Severe Nonproliferative Diabetic Retinopathy	Jun Kong, MD, PhD	3:15 PM
		Discussion		3:18 PM
3:40 PM	4:15 PM	Retinal Vascular Disease Symposium 1	Moderators: Sunir J Garg, MD, FACS, FASRS; James C	
			Major, MD, PhD FACS FASRS; Adrienne W Scott, MD,	
			FASRS	
		Timing of Ocular Adverse Events in Pooled Analysis of Two Phase 3 Trials of Revakinagene Taroretcel (NT-501)	Dean Eliott, MD	3:40 PM
		in Macular Telangiectasia Type 2		
		Elevated Short-Term Risk of Stroke Following Retinal Artery Occlusion: A Large Integrated Health System	Robin A. Vora, MD	3:43 PM
		Analysis		
		Visual Recovery in Patients With Central Retinal Artery Occlusions Treated With Intravenous Thrombolysis	Bobeck S. Modjtahedi, MD	3:46 PM
		The Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Risk of Retinal Vein and Artery Occlusions	Aleksandra V. Rachitskaya, MD, FASRS	3:49 PM
		Identification of Risk Factors Associated With Development or Progression of Proliferative Sickle Cell	Adrienne W. Scott, MD, FASRS	3:52 PM
		Retinopathy	The state of the s	5.52
		Surgical Outcomes for Proliferative Sickle Cell Retinopathy	Hesham Gabr, MD	3:55 PM
		Discussion		3:58 PM
4:15 PM	4:45 PM	Retinal Vascular Disease Symposium 2	Moderators: Sharon Fekrat, MD FACS FASRS; Suber S	5.55114
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Huang, MD, MBA, FASRS; Robin A Vora, MD	
		From Bench to Bedside in CSCR: Discovery of a Rare Genetic Risk Variant and Correlation With In-Human Data	Elizabeth Rossin, MD, PhD	4:15 PM
		Using Faricimab		
		Associations Between Androgen Exposure, PCOS, and Transmasculine Individuals With Central Serous	Danny A. Mammo, MD	4:18 PM
			, , , , , , , , , , , , , , , , , , , ,	1

		Aflibercept 8 mg in Treatment-Naive Macular Edema Secondary to Retinal Vein Occlusion: Primary Endpoint	Seenu M. Hariprasad, MD	4:21 PM
		Results From the QUASAR Study		
		Intracameral Delivery of Bevacizumab in the Management of Anterior Segment Recalcitrant Neovascular	Marib I. Akanda, MD	4:24 PM
		Complications of Proliferative Vascular Retinopathies		
		First In-Human Study Using a Novel Suprachoroidal Injector	Yoreh Barak, MD	4:27 PM
		Discussion		4:30 PM
4:45 PM	5:06 PM	Case-Based Discussion: Retinal Vascular Disease	Moderators: Diana V. Do, MD, FASRS	4:45 PM
		Panelists: Manjot Gill, MD, MS, FRCS (C), FASRS; Alice T. Lyon, MD, FASRS; Ramsudha Narala, MD; Sally S. Ong,		
		MD; Karen M. Wai, MD		
7:00 PM	11:59 PM	Gala: The Queen Mary		